ResMed (NYSE: RMD) reported Q1 EPS of $2.20, $0.15 better than the analyst estimate of $2.05. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.19 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.